Reassortant Or Deletion Mutant Virus Patents (Class 424/205.1)
-
Patent number: 7758867Abstract: The present invention relates to an isolated attenuated influenza virus strain and a live vaccine comprising the same. The isolated attenuated influenza virus strain is prepared by cold-adaptation of a mother strain which carries 6 internal genomes of A/PR/8/34(H1N1) and two surface antigens HA and NA of A/Aichi/2/68(H3N2). The attenuated influenza virus strain and the live vaccine of the present invention are useful for prevention of seasonal influenza episodes and sudden outbreak of influenza pandemics of predicted or unknown identity, since they have safety, efficacy, high production yield, immediate protection against variety of influenza subtypes and prolonged protection against specific influenza subtype.Type: GrantFiled: June 18, 2007Date of Patent: July 20, 2010Assignee: Biotrion Co., Ltd.Inventors: Baik Lin Seong, Kwang Hee Lee, Sang Uk Seo
-
Patent number: 7754221Abstract: Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proferating proliferating tissues, particularly tumors, to produce selected proteins and other products. Vaccines containing the microorganisms are provided. Combinations of the microorganisms and anti-cancer agents and uses thereof for treating cancer also are provided.Type: GrantFiled: July 28, 2009Date of Patent: July 13, 2010Assignee: Genelux CorporationInventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
-
Patent number: 7749745Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: GrantFiled: March 27, 2002Date of Patent: July 6, 2010Assignees: Georgetown University, The General Hospital Corporation, MediGene, Inc.Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
-
Patent number: 7731974Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 29, 2004Date of Patent: June 8, 2010Assignees: Ottawa Hospital Research Institute, Wellstat Biologics CorporationInventors: John C. Bell, Brian D. Lichty, David F. Stojdl
-
Publication number: 20100136047Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) is a major problem in the pork industry worldwide. The inclusion of markers in vaccines will allow for diagnostic differentiation of vaccinated animals from those naturally infected with wild-type virus. Using a cDNA infectious clone of North American Type 1 PRRSV, a recombinant green fluorescent protein (GFP) tagged PRRSV has been made, containing deletion of an immunogenic epitope, ES4, in the nsp2 region. GFP and ES4 epitope-based ELISAs compliment the marker identification.Type: ApplicationFiled: June 24, 2008Publication date: June 3, 2010Applicant: South Dakota State UniversityInventors: Ying Fang, Eric A. Nelson, Jane Hennings
-
Patent number: 7682619Abstract: The present invention relates to an isolate canine influenza virus. The present invention relates to an isolated nucleic acid molecule encoding a hemagglutinin from a canine influenza virus. The present invention also relates to the protein or polypeptide encoded by the isolated nucleic acid molecule. Vaccines and detection and treatment methods relating to canine influenza viruses are also disclosed.Type: GrantFiled: April 5, 2007Date of Patent: March 23, 2010Assignee: Cornell Research Foundation, Inc.Inventor: Edward J. Dubovi
-
Patent number: 7674468Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: GrantFiled: June 13, 2005Date of Patent: March 9, 2010Assignees: Crusade Laboratories Limited, The Wistar InstituteInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Patent number: 7666433Abstract: The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineered with deletions of amino acids 151-221 and 178-219. Both RSV strains replicated in the respiratory tract of BALB/c mice and elicited serum neutralization and anti-F protein IgG titers that were equivalent to cp-RSV and contributed to a 3.9 log10 reduction in RSV A2 four days after challenge. Importantly, pulmonary eosinophilia was significantly diminished in BALB/c mice primed with native G protein and challenged with either recombinant RSV strain. These findings are important for the development of immunogenic compositions against RSV.Type: GrantFiled: June 29, 2005Date of Patent: February 23, 2010Assignee: Wyeth Holdings CorporationInventors: Gerald E. Hancock, Matthew B. Elliott
-
Publication number: 20100015179Abstract: The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, CVEE30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of CVEE, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of CVEE by its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.Type: ApplicationFiled: August 15, 2008Publication date: January 21, 2010Inventors: Ilya V. Frolov, Elena Frolova, Scott C. Weaver
-
Publication number: 20090304738Abstract: The present invention is directed to methods for enhancing immune responses. Such methods serve to enhance dendritic cell activation, which, in turn, promotes a more robust immune response to foreign antigens. As such, the methods and compositions of the invention are for useful in the context of a variety of prophylactic and therapeutic regimens.Type: ApplicationFiled: June 15, 2006Publication date: December 10, 2009Inventors: Thomas M. Moran, Carolina B. Lopez, Jacob Yount
-
Publication number: 20090297557Abstract: Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Bocavirus-2, and variants thereof. Also provided are methods of detecting the Bocavirus-2 and diagnosing Bocavirus-2 infection, methods of treating or preventing Bocavirus-2 infection, and methods for identifying anti-Bocavirus-2 compounds.Type: ApplicationFiled: April 17, 2009Publication date: December 3, 2009Applicant: Blood Systems, Inc.Inventors: Eric Delwart, Amit Kapoor
-
Publication number: 20090297552Abstract: Vaccines that comprise or generate immunomodulatory flagellin polypeptides able to stimulate an innate immune response intracellularly and extracellularly employ viruses, bacteria or parasitic cells that contain expression systems for such polypeptides, as well as fusion proteins that contain antigens and/or cell penetrating peptides along with the immunomodulatory peptide.Type: ApplicationFiled: April 24, 2009Publication date: December 3, 2009Inventors: Alan A. Aderem, Edward A. Miao, Carrie M. Rosenberger
-
Patent number: 7622125Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.Type: GrantFiled: May 5, 2005Date of Patent: November 24, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan zur Megede, Susan W. Barnett
-
Publication number: 20090285853Abstract: The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.Type: ApplicationFiled: July 23, 2009Publication date: November 19, 2009Applicant: MEDIMMUNE, LLCInventors: Xing Cheng, Hyun Jung Park, Hong Jin
-
Publication number: 20090285852Abstract: The invention provides a method for enhancing expression of a transgene in a host cell, which includes the steps of inserting a capsid promoter element (Pcap), or a sequence comprising the reverse complement of the capsid promoter element (PcapR), into a mammalian expression cassette upstream (5?) of a cytomegalovirus immediate/early enhancer/promoter region (Pcmv); inserting the transgene into the expression cassette downstream (3?) of the cytomegalovirus immediate/early enhancer/promoter region; inserting a vector containing the expression cassette into the host organism; and causing expression of the transgene. The capsid promoter element (Pcap) is typically from a circovirus, parvovirus or anellovirus. The transgene is typically expressed at a higher level than when expressed by a vector containing the expression cassette without the transcriptional control element. An expression cassette, vector, DNA vaccine, pharmaceutical composition and method of treatment are also claimed.Type: ApplicationFiled: November 8, 2006Publication date: November 19, 2009Inventors: Edward Peter Rybicki, Fiona Lesley Tanzer
-
Publication number: 20090285879Abstract: Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.Type: ApplicationFiled: December 23, 2008Publication date: November 19, 2009Applicants: Crucell Holland B.V., GlaxoSmithKline Biologicals S.A., on behalf of the Walter Reed Army Institute ResearchInventors: Maria Grazia Pau, Jaap Goudsmit, Joseph D. Cohen, Patrice Dubois, V. Ann Stewart, Donald Heppner
-
Patent number: 7611718Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.Type: GrantFiled: December 20, 2006Date of Patent: November 3, 2009Assignee: MedImmune, LLCInventors: George Kemble, Gregory M. Duke, Richard Spaete
-
Publication number: 20090246216Abstract: A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5? non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2aCD155 tumors) expressing CD155, the poliovirus receptor, and is effective for oncolytic treatment and cure of solid tumors, such as neuroblastoma.Type: ApplicationFiled: March 16, 2009Publication date: October 1, 2009Applicant: The Research Foundation of State University of New YorkInventors: Eckard Wimmer, Jeronimo Cello, Aniko Paul, Hidemi Toyoda, Jiang Yin
-
Publication number: 20090238843Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
-
Patent number: 7588767Abstract: Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism as well as antibodies reactive therewith are provided.Type: GrantFiled: June 18, 2004Date of Patent: September 15, 2009Assignee: Genelux CorporationInventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
-
Patent number: 7589069Abstract: Novel vectors which are replication competent in neoplastic cells and which overexpress an adenovirus death protein are disclosed. Some of the disclosed vectors are replication-restricted to neoplastic cells or to neoplastic alveolar type II cells. Compositions and methods for promoting the death of neoplastic cells using these replication-competent vectors are also disclosed.Type: GrantFiled: July 12, 1999Date of Patent: September 15, 2009Assignee: Saint Louis UniversityInventors: William S. M. Wold, Karoly Toth, Konstantin Doronin, Ann E. Tollefson
-
Publication number: 20090226488Abstract: Attenuated pestiviruses, in particular attenuated BVDV, wherein at least one mutation is in the coding sequence for glycoprotein Ems and at least another mutation in the coding sequence for Npro which preferably leads to combined inactivation of the RNase activity residing in glycoprotein Ems in addition to the inactivation of the (hypothesized) immunomodulating activity residing in Npro. Methods for attenuating pestiviruses such as BVDV, nucleic acids encoding the pestiviruses, in particular BVDV, compositions and vaccines comprising the attenuated pestiviruses, in particular BVDV, of the invention.Type: ApplicationFiled: May 11, 2009Publication date: September 10, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Gregor MEYERS, Andreas EGE, Christiane MEYER, Martina von FREYBURG
-
Publication number: 20090214590Abstract: The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject.Type: ApplicationFiled: July 10, 2006Publication date: August 27, 2009Applicant: Wayne State UniversityInventors: Roy Sundick, Paul Christopher Roberts, Yufang Yang, Andrew Scott Herbert
-
Publication number: 20090191239Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.Type: ApplicationFiled: January 30, 2009Publication date: July 30, 2009Inventors: Martha A. Wild, Mark D. Cochran
-
Publication number: 20090191149Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.Type: ApplicationFiled: May 15, 2007Publication date: July 30, 2009Applicant: XBIOTECH INC.Inventor: John Simard
-
Patent number: 7566458Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: June 16, 2004Date of Patent: July 28, 2009Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 7563448Abstract: Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG oligodeoxynucleotide immunomodulators.Type: GrantFiled: May 21, 2007Date of Patent: July 21, 2009Assignee: City of HopeInventors: Joshua D.I. Ellenhorn, Don J. Diamond
-
Publication number: 20090181078Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: January 9, 2009Publication date: July 16, 2009Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20090181052Abstract: A method for prevention of HPV infection and/or disease, the method comprising delivery of a first HPV vaccine comprising an L1 protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 L1 components from the first vaccine, and which second vaccine comprises an L1 protein or immunogenic fragment thereof from at least one other oncogenic HPV type, wherein the first and second vaccines may be delivered in either order and delivery is separated by a suitable time interval.Type: ApplicationFiled: April 24, 2006Publication date: July 16, 2009Inventor: Brigitte Desiree Alberte Colau
-
Patent number: 7560117Abstract: The present invention relates to a highly processive reverse transcriptase having DNA polymerase activity and substantially reduced protease activity. More specifically, the invention relates to an isolated reverse transcriptase from foamy virus comprising a substantially inactivated protease. The invention also relates to vectors containing the gene and hosts transformed with the vector of the invention. Further, the invention relates to a method for producing reverse transcriptase having DNA polymerase activity and substantially reduced protease activity by expressing the reverse transcriptase genes of the present invention in a recombinant host. Methods are also provided for producing cDNA from polynucleotides using the highly processive reverse transcriptase of the invention. Kits for the preparation of cDNA from RNA comprising the highly processive reverse transcriptase of the invention are also provided.Type: GrantFiled: May 22, 2002Date of Patent: July 14, 2009Assignee: Fred Hutchinson Cancer Research CenterInventors: Stephen Hughes, Paul Boyer, Maxine Linial, Carolyn Stenbak, Patrick Clark
-
Publication number: 20090175905Abstract: A transfection reagent and a method for enhancing transfection efficiency are described. A nucleic acid is provided, and a disaccharide is added as a transfection reagent. The disaccharide is composed of two identical monosaccharides. The transfection reagent is then applied to cells to introduce the nucleic acid into the cells.Type: ApplicationFiled: July 4, 2008Publication date: July 9, 2009Applicant: National Taiwan University of Science and TechnologyInventors: Wen-Chi Tseng, Tsuei-Yun Fang, Chien-Hsiang Tang
-
Publication number: 20090175906Abstract: The present invention relates to methods for generating genetically modified and attenuated strains of vesicular stomatitis virus (VSV) for use in the preparation of immunogenic compositions. More particularly, the invention relates to the identification of particular genetic modifications of attenuated VSV that result in an increased yield of virus and an increase in stability of the attenuated strains for preparation of the immunogenic compositions. Methods for cell culture propagation and use in large scale production of VSV is also disclosed.Type: ApplicationFiled: December 18, 2008Publication date: July 9, 2009Applicant: WyethInventors: Narender Kumar Kalyan, Irina Yurgelonis, Roger Michael Hendry, Mark William Cutler, Kristen Elissa Syvertsen
-
Patent number: 7550149Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.Type: GrantFiled: December 21, 2006Date of Patent: June 23, 2009Assignee: MedImmune, LLCInventors: George Kemble, Gregory M. Duke, Richard Spaete
-
Patent number: 7537770Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.Type: GrantFiled: December 20, 2006Date of Patent: May 26, 2009Assignee: MedImmune, LLCInventors: George Kemble, Gregory M. Duke, Richard Spaete
-
Publication number: 20090123494Abstract: The present invention discloses Moloney murine leukemia virus (MoMLV)-based viral packaging cell line for the production of anti-viral vaccines. The invention also includes methods of making, administering and formulating pseudovirions and replicon deficient viral particles of the invention and methods of inducing immunity.Type: ApplicationFiled: July 31, 2008Publication date: May 14, 2009Inventors: William Staplin, Robert Mandell, Ramon Flick
-
Patent number: 7527800Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: May 20, 2005Date of Patent: May 5, 2009Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Patent number: 7524508Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.Type: GrantFiled: September 5, 2003Date of Patent: April 28, 2009Assignee: The United states of America as represented by the Department of Health and Human ServicesInventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
-
Patent number: 7517531Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: October 21, 2004Date of Patent: April 14, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Publication number: 20090092636Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein.Type: ApplicationFiled: June 11, 2008Publication date: April 9, 2009Applicant: BOEHRINGER INGELHEIM VETMEDICA, INCInventors: Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel
-
Patent number: 7510719Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.Type: GrantFiled: December 7, 2005Date of Patent: March 31, 2009Assignee: MedImmune, LLCInventors: Qi Dang, Richard Schwartz
-
Patent number: 7507411Abstract: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.Type: GrantFiled: June 11, 2007Date of Patent: March 24, 2009Assignee: University of SaskatchewanInventors: Yan Zhou, Yeun-Kyung Shin, Lorne A. Babiuk, Qiang Liu
-
Publication number: 20090017064Abstract: The present invention relates to compositions and methods of eliciting a cross-protective immune response against a pathogenic porcine circovirus by administering to a pig an immunogenically effective amount of a type 1-type 2 chimeric porcine circovirus vaccine. The chimeric vaccine utilized for cross-protection may be administered as a single dose or as multiple doses. The invention further relates to protection of the pig from any one or more of the symptoms or sequelae associated with postweaning multisystemic wasting syndrome (PMWS). Moreover, the administering of the chimeric vaccine also results in reduction in the higher than average mortality associated with the high mortality type 2B strains of porcine circovirus.Type: ApplicationFiled: July 9, 2008Publication date: January 15, 2009Applicant: WyethInventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Publication number: 20080317778Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: ApplicationFiled: August 28, 2008Publication date: December 25, 2008Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20080317825Abstract: The present invention is directed to a pharmaceutical preparation for oral application for treatment of fish, in particular for vaccination of fish of the salmon family and other fish having a comparable digestive system against bacterial and/or viral infections, in particular against VHS and IHN. The invention is also directed to a method for producing the preparation.Type: ApplicationFiled: December 13, 2005Publication date: December 25, 2008Applicant: RIEMSER ARZNEIMITTEL AGInventors: Malte Adelmann, Dieter Fichtner, Bodo Lange, Werner Weitschies
-
Publication number: 20080305129Abstract: The present invention relates to highly attenuated animal smallpox viral strains and to the use thereof as paramunity inducers or for producing vector vaccines. As a result of the high attenuation process, the claimed animal smallpox strains lose their virulent and immunising properties. The invention also relates to a method for producing such highly attenuated pox virus strains and the use thereof for inducing paramunity, i.e. for activating the non-specific immune system in mammals and humans or for producing vector vaccines for specific immunisation with the positive side-effect of paramunisation. The claimed highly attenuated animal smallpox viruses are thus suitable for preventing and treating diseases associated with an immune deficiency. Preferred embodiments relate to highly attenuated orthopox—(e.g. camel smallpox viruses), leporipox—(e.g.Type: ApplicationFiled: June 16, 2006Publication date: December 11, 2008Inventor: Anton Mayr
-
Patent number: 7459154Abstract: Agents and methods for enhancing recombinant virus transduction in the bladder epithelium are described. A first method involves contacting the luminal surface of the bladder with a composition comprising a transduction enhancing agent and an oncolytic virus. Alternatively, the luminal surface of the bladder can be contacted first with a pretreatment composition comprising a transduction enhancing agent and, subsequently, with a composition comprising an oncolytic virus. Bladder treatment compositions comprising a transduction enhancing agent and an oncolytic virus are also described.Type: GrantFiled: December 26, 2002Date of Patent: December 2, 2008Assignee: Cell Genesys, Inc.Inventors: Nagarajan Ramesh, David Frey, Bahram Memarzadeh, DeChao Yu
-
Patent number: 7455842Abstract: A chimeric West Nile live virus comprised of the NY99 and WN1415 strains and an infectious DNA recombinant construct encoding for the chimeric virus are provided, as well as immunogenic compositions and their method of use.Type: GrantFiled: December 5, 2005Date of Patent: November 25, 2008Assignee: University of KansasInventor: Vladimir F. Yamshchikov
-
Publication number: 20080279892Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.Type: ApplicationFiled: March 26, 2007Publication date: November 13, 2008Applicant: MedImmune Vaccines, Inc.Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Publication number: 20080279891Abstract: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.Type: ApplicationFiled: July 8, 2005Publication date: November 13, 2008Inventors: Robert E. Johnston, Joseph M. Thompson
-
Publication number: 20080274130Abstract: Rabies Virus compositions and methods are provided. The full-length sequence of Rabies Virus strain Evelyn-Rokitnicki-Abelseth (ERA) is disclosed. A reverse genetics system for producing recombinant ERA virus and derivatives thereof is provided, along with compositions including ERA and/or ERA derivative strain viruses, nucleic acids and/or proteins. In some instances, the compositions are immunogenic compositions useful for the pre- or post-exposure treatment of Rabies Virus.Type: ApplicationFiled: October 13, 2006Publication date: November 6, 2008Applicant: The Govt. of the U.S.A. as Represented by the Secretary of the Dept.of Health and Human ServicesInventors: Charles E. Rupprecht, Xianfu Wu